If you have celiac disease, one slip with gluten can damage your gut, and a strict gluten-free diet is still the only treatment available. Even careful patients get caught out, and symptoms persist in up to 40 percent of people on the diet. That is why a new phase 2 trial is getting attention. In a study of 126 adults with celiac disease, an experimental drug called FB102 helped protect the intestinal lining during a controlled gluten challenge better than a placebo. It’s an early result, and it doesn’t mean anyone can eat gluten freely. Here is what the trial tested, how the drug works, and what has to happen before it could reach patients.
Why a Gluten-Free Diet Isn’t Always Enough
Celiac disease is an autoimmune condition. When a person with celiac eats gluten, the immune system attacks the lining of the small intestine, and even a small amount can cause damage.
The damage is specific. The small intestine is lined with tiny, finger-like projections called villi, which absorb nutrients from food. In people with celiac disease, gluten shortens these projections and deepens the grooves between them. Less surface area means less absorption, and over time that can lead to nutritional deficiencies.
Right now, the only treatment is a strict gluten-free diet. It works, but it leaves very little room for error. Even when people check every label, accidental exposure happens, and the diet doesn’t fully control symptoms for everyone. Symptoms persist in up to 40 percent of patients.
That is the gap researchers are trying to close. No approved drug can currently protect the gut from accidental gluten exposure. Several experimental drugs are being tested, and one of them has just cleared a phase 2 trial.
126 Patients, One Gluten Challenge
Researchers enrolled 126 adults with confirmed celiac disease. All of them had followed a strict gluten-free diet for at least a year and had no symptoms.
They were split into three groups by random assignment. Two groups received FB102 through an IV drip, each at a different dose, and one group received a placebo, an infusion with no active drug. Neither the participants nor the researchers knew who got what. That setup keeps expectations from skewing the results.
For eight weeks, everyone also ate gluten on purpose, under controlled conditions. This was the test: could the drug protect the gut while it was being exposed to gluten?
To find out, the researchers compared the height of the villi, the tiny finger-like projections that absorb nutrients, with the depth of the grooves between them. A healthy gut has tall villi and shallow grooves. Gluten damage flattens the villi and deepens the grooves, so the ratio drops. At day 78, the ratio had held up significantly better in people who received FB102 than in those who received the placebo. The statistical result (p=0.0176) falls below the standard 0.05 cutoff, which means the difference was unlikely to be due to chance.
People on FB102 also had fewer signs of gluten injury and a smaller inflammatory immune response in the lining of the gut. No new safety concerns came up compared with earlier studies of the drug.
How FB102 Works
FB102 is an antibody, a lab-made protein designed to attach to one specific target. That target is CD122, a receptor on the surface of certain immune cells. Think of a receptor as a docking point: when an inflammatory signal attaches to it, the cell gets the message to act.
CD122 picks up signals from two messengers called IL-2 and IL-15, which help activate and sustain the immune cells that drive disease. Researchers believe these signals play a central role in how celiac disease starts and keeps going. In 2009, a study showed that blocking this receptor in mice with autoimmune gut problems reversed their intestinal damage. That finding led to the idea of testing the same approach in people with celiac disease.
FB102 was built to block CD122 on only some of the immune cells that cause trouble, and to leave it working on others. The company says this preserves the regulatory T cells, which help keep the immune system in balance. The goal is to calm the faulty response to gluten without shutting down immune defenses more broadly.
The drug was developed by Forte Biosciences, which argenx acquired in August 2026. Before the phase 2 trial, an earlier phase 1b study had already pointed in the same direction, showing that blocking CD122 protected against gluten-induced gut damage and prevented symptoms. The FDA has also granted FB102 Fast Track designation for celiac disease, a status that speeds up development and review of drugs for serious conditions with few or no treatment options.
Promising, but Not a Green Light to Eat Gluten
FB102 doesn’t give people with celiac disease permission to eat gluten freely. The drug was tested under controlled conditions, and it’s unclear whether the protection holds in daily life, where exposure is accidental and varies in amount.
The data also have limits. These are topline results announced by argenx, and they haven’t been peer-reviewed. The company hasn’t shared how large the effect was, how the two doses compared, or the detailed secondary results. A significant p-value tells us the difference was probably not due to chance. It doesn’t tell us how much it matters to a patient. The trial also enrolled only people who were symptom-free on a gluten-free diet, so we don’t know how the drug works in people whose symptoms persist despite the diet.
Full results are expected at an upcoming medical meeting, and argenx plans to move FB102 into phase 3. The bar for approval is high. According to the FDA’s draft guidance, a drug taken long term would need to show efficacy over at least 52 weeks, and without a gluten challenge. This trial’s challenge lasted eight weeks.
The research isn’t limited to celiac disease. FB102 is also being studied in vitiligo, a condition in which skin loses its pigment in patches, and researchers suspect it could help with alopecia areata, an autoimmune cause of hair loss. If the CD122 approach holds up, it could apply to several immune-driven conditions.
For patients today, nothing changes. Stay on a strict gluten-free diet and talk to your doctor before changing how you manage your condition.
My Personal RX on Protecting Your Gut Every Day
Whether you have celiac disease, a gluten sensitivity, or simply want better digestion, the lining of your small intestine matters. It absorbs the nutrients your body needs. Drugs like FB102 are still in testing, so daily habits do the heavy lifting right now.
Here are my personal tips.
- Get Tested Before You Cut Gluten: Going gluten-free first can make celiac disease harder to diagnose. See your doctor before changing your diet.
- Read Every Label: Gluten shows up in sauces, soups, and processed foods. Recipes change, so check each time.
- Prevent Cross-Contact: Use separate toasters, cutting boards, and colanders at home. At restaurants, ask how your food is prepared.
- Lean on Naturally Gluten-Free Foods: Vegetables, fruit, eggs, fish, and rice need no label decoding.
- Check for Nutrient Gaps: Gut damage can lower your absorption of iron, calcium, and vitamin D. Ask your doctor to check your levels.
- Support Your Digestion: My Gut Brain Reset Bundle combines MindBiotic, Digestive Enzymes, and Eye Max to support digestion, microbiome balance, and nutrient absorption. Supplements support your gut, but they don’t replace a gluten-free diet if you have celiac disease.
- Manage Stress: Stress can aggravate digestive symptoms through the gut-brain axis. Try deep breathing or a daily walk.
- Prioritize Sleep: Aim for seven to nine hours. Your gut and immune system both need the rest.
- Learn the Science: My book, Heal Your Gut, Save Your Brain, explains how gut health shapes mood and cognition.
- Stay on the Diet: FB102 is promising but not approved. Until your doctor says otherwise, a strict gluten-free diet remains the treatment. Ask your doctor about new trials.
Sources:
- Lapid, N. (2026, October 14). Experimental drug treats gluten-caused intestinal damage in celiac patients. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/experimental-drug-treats-gluten-caused-intestinal-damage-celiac-patients-2026-10-14/
- Randomized, double blind, placebo-controlled phase 2 study in adults with celiac disease – mayo clinic. (2026, May 27). Mayo Clinic. https://www.mayo.edu/research/clinical-trials/cls-20597947
